Twenty four male Sprague-Dawley rats (3 months old, weighing 250-300 g).
Dosage:
20 mg/kg.
Administration:
IP, daily at 8:00 p.m.
Result:
Resulted in significantly decreased plasma glucose levels (6.670.35 mmol/L, 6.770.34 mmol/L vs. 8.27 0.38 mmol/L), and the plasma glucose levels of the two groups were even neared to that of the normal control group (6.07±0.35 mmol/L).
Resulted in a decrease in triglycerides and total cholesterol levels (51.8% and
43.0%, respectively) and an elevation in HDL-C level (increase of 32.4%).
Animal Model:
Five groups of 12-wk-old rats (10/group).
Dosage:
5-50 mg/kg.
Administration:
Intraperitoneal injection in 18:00 every day.
Result:
Plasma glucose was decreased significantly by 27.3%, 34.5% and 61.5%, respectively.
Animal Model:
Male C57BL/6 J mice, weighing 22-26 g (10 weeks old; PSL mice).
Dosage:
25, 50, or 100 mg/kg.
Administration:
IP 1 h before assessment of thermal hyperalgesia and mechanical allodynia.
Result:
Remarkably prolonged thermal latency (surgery×treatment interaction, F1,24=15.7, p<0.001; surgery×treatment×hours interaction, F5,120=3.0, p<0.05) and increased mechanical threshold (surgery×treatment interaction, F1,24=18.4, p<0.001; surgery× treatment×hours interaction, F5,120=2.6, p<0.05) for 4 h after administration of piromelatine to PSL mice.
分子式
C17H16N2O4
分子量
312.32
CAS号
946846-83-9
运输条件
Room temperature in continental US; may vary elsewhere.